We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Advisory Committee Unanimously Supports Perrigo’s OTC Bid for Oral Contraceptive
Advisory Committee Unanimously Supports Perrigo’s OTC Bid for Oral Contraceptive
Despite the FDA’s lingering concerns over study data, a 17-member advisory committee unanimously supported Perrigo’s bid to switch its progestin-only oral contraceptive Opill (norgestrel 0.075 mg) from prescription to OTC.